Although administration of ibrutinib (a Bruton tyrosine kinase inhibitor) was shown to increase the risk for development of AF, the pro-arrhythmic effects of ibrutinib resulted from inhibition of C-terminal Src kinase but not inhibition of tyrosine kinase (67). The gene discussed is BTK; the disease is atrial fibrillation.